NRXP NRX Pharmaceuticals Inc
12,805
$3.06
$0.96
(45.71%)
| Watchers | 12,805 |
| 52-Wk Low | $1.90 |
| 52-Wk High | $12.00 |
| Market Cap | $29.28M |
| Volume | 33,173.00 |
| 52-Wk High | $12.00 |
| 52-Wk Low | $1.90 |
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionPR Newswire • about 23 hours ago
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression...
Share to Feed
NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.
read more...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression NRx Pharmaceuticals (Nasdaq:NRXP...
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq...
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of...
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock PR Newswire RADNOR...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential...
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary...
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase...